VANGUARD GROUP INC 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 10:16 am Sale | 2026-03-13 | 13G | KEROS THERAPEUTICS INC KROS | VANGUARD GROUP INC | 0 0.000% | -1,525,355 (Position Closed) | Filing |
| 2026-01-30 2:17 pm Sale | 2025-12-31 | 13G | KEROS THERAPEUTICS INC KROS | VANGUARD GROUP INC | 1,525,355 5.000% | -1,040,966 (-40.56%) | Filing |
| 2025-04-30 11:23 am Purchase | 2025-03-31 | 13G | KEROS THERAPEUTICS INC KROS | VANGUARD GROUP INC | 2,566,321 6.320% | 2,566,321 (New Position) | Filing |